Aytu Biopharma, Inc. income statement AYTU

Annual Quarterly

In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, Aytu Biopharma, Inc. reported revenue of $16.1 million, up 6.4% from the same quarter a year earlier. It recorded a net loss of $15,000. The operating loss came to $777,000, an operating margin of -4.8%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Q4 FY2026
Jun 30, 2026
Q3 FY2026
Mar 31, 2026
Q2 FY2026
Dec 31, 2025
Q1 FY2026
Sep 30, 2025
Q4 FY2025
Jun 30, 2025
Q3 FY2025
Mar 31, 2025
Q2 FY2025
Dec 31, 2024
Q1 FY2025
Sep 30, 2024
Revenue
16
+6.4%
12
-32.7%
15
-6.5%
14
-16.2%
15
+3.7%
18
+31.6%
16
-13.5%
17
-7.0%
Cost of revenue
6
+16.7%
5
-14.8%
6
+2.0%
5
+2.5%
5
+37.8%
6
+54.1%
5
+31.1%
5
-4.0%
Gross profit
10
+1.5%
8
-40.7%
10
-10.8%
9
-23.4%
10
-7.2%
13
+23.6%
11
-26.1%
12
-8.1%
Research and development
0
-100.0%
0
-100.0%
0
-100.0%
0
-100.0%
0
-79.3%
0
-73.5%
1
+0.2%
0
-28.4%
Selling, general and administrative
10
+23.0%
11
+17.2%
11
+13.9%
10
-5.0%
8
-10.3%
9
-8.6%
10
-3.0%
11
-12.9%
Restructuring and impairment
0
0
0
-100.0%
0
-100.0%
0
0
1
1
Operating income
-1
+89.8%
-4
-267.9%
-2
-16.2%
-2
-61.7%
-8
-235.4%
2
+251.6%
-2
-153.9%
-1
-7.3%
Pretax income
-0
+100.0%
-6
-246.9%
-11
-2870.7%
2
+31.2%
-19
-666.4%
4
+316.1%
0
-72.7%
1
+120.0%
Income tax
0
-97.5%
0
+108.2%
0
+100.0%
0
-100.0%
0
-48.0%
-0
-123.4%
-0
-136.3%
0
Net income
-0
+99.9%
-6
-240.7%
-11
-1443.1%
2
+33.3%
-20
-329.2%
4
+238.3%
1
+458.2%
1
+118.2%
Basic EPS
-0.00
+100.0%
-0.53
-181.5%
-1.05
-907.7%
0.21
-12.5%
-2.92
-255.5%
0.65
+225.0%
0.13
+425.0%
0.24
+116.2%
Diluted EPS
—
-0.53
-352.4%
-1.05
-303.8%
-0.08
+46.7%
—
0.21
-0.26
-0.15
+89.9%
Weighted average shares, basic
19
+184.4%
11
+71.3%
10
+63.7%
9
+55.6%
7
+20.7%
6
+10.9%
6
+11.1%
6
+10.7%
Weighted average shares, diluted
—
11
+28.1%
10
+18.3%
19
+114.0%
—
8
8
9
+66.0%
Other measures
Depreciation and amortization
0
0
+0.0%
0
+0.0%
0
0
-100.0%
0
-50.0%
0
-66.7%
—
EBITDA
-1
+89.8%
-4
-257.2%
-2
-17.2%
-1
-8
-250.8%
3
+280.5%
-2
-146.3%
—
Interest coverage
-2.03x
-9.32x
-3.52x
-2.91x
-10.44x
2.69x
-1.57x
-0.94x
Margins
Gross margin
64.63%
61.23%
63.46%
66.14%
67.75%
69.40%
66.49%
72.31%
Operating margin
-4.82%
-32.75%
-12.99%
-10.83%
-50.37%
13.12%
-10.45%
-5.61%
Pretax margin
-0.02%
-45.19%
-69.79%
14.15%
-128.46%
20.69%
2.35%
9.04%
Profit margin
-0.09%
-45.27%
-69.79%
14.15%
-130.94%
21.65%
4.86%
8.89%
EBITDA margin
-4.82%
-31.94%
-12.33%
-10.11%
-50.37%
13.66%
-9.83%
—
Effective tax rate
—
—
—
0.00%
—
-3.20%
-74.08%
27.04%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AYTU (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
Denver, CO
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1385818
Former names
AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.